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Abstract: Neuropathic pain (NeP) syndromes remain a difficult-to-treat medical entity. Despite 
a growing number of pharmacological and invasive analgesic therapies the results remain 
less than optimal because of insufficient analgesic efficacy and/or occurrence of pronounced 
side effects. Current guidelines propose the use of multimodal and balanced pharmacological 
therapies, focused on the underlying pathophysiological mechanisms (mechanistic approach). 
Lidocaine 5% patches are a new treatment option currently licensed for the treatment of posther-
petic neuralgia. However, these patches can also be used for the treatment of different types of 
superficial NeP syndromes, such as diabetic polyneuropathy. Their therapeutic success, however, 
largely depends on the correct identification of appropriate patients and pain syndromes. This 
manuscript outlines the correct identification of patients and proper use of these patches in order 
to ensure as much as possible the therapeutic efficacy of this new treatment option.
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Introduction
Despite considerable progress in the treatment options for neuropathic pain (NeP) 
these conditions still remain very difficult to treat.1 NeP remains a clinical challenge 
for several reasons, one of course being the specific pathophysiological features that 
underlie the occurrence of a painful neuropathic syndrome. A growing body of evi-
dence indicates the presence of specific and multifactor alterations at several levels of 
the nervous system during NeP syndromes.2–6 Additionally, NeP patients often display 
co-morbidities that render the use of (strong) analgesics and/or additive drugs (such 
as anti-depressants and anti-epileptic agents) extremely difficult. This often leads to a 
trial-and-error approach, initiating and (rapidly) interrupting drugs due to side effects. 
Drugs are often used in suboptimal dosages to try to avoid negative interactions with 
concomitant drugs or potentially dangerous systemic side effects, which leads to 
suboptimal treatment strategies, leaving the patient in pain and inducing a state where 
the patients will start taking additional (rescue medications) analgesics (often OTC) 
in an irregular and uncontrolled manner.
Treatment strategies for NeP should therefore be significantly revised, by introduc-
ing target-specific treatment options. Such treatment should be focused on the specific 
sensory syndrome present in the patient, thereby specifically targeting cutaneous dis-
turbances that are present. In this respect, lidocaine 5% patches can lead to an entirely 
new and exciting approach to a subset of NeP syndromes. However, the success of such 
specific treatment probably largely depends on the proper identification of the most Clinical Pharmacology: Advances and Applications 2010:2 66
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suitable patients. The purpose of this manuscript is therefore 
to provide clinicians with the proper tools for identifying such 
patients, by detailing the appropriate sensory syndromes, and 
identifying suitable places for the application of the patches 
and other patient characteristics.
Case report 1
A 74-year-old woman developed a herpes zoster skin rash 
after the death of her husband. Although she was quickly 
diagnosed and treated with oral anti-viral medications 
  (acyclovir), she soon developed stabbing and burning pain in 
the entire area of the skin rash (dermatomes D7 till D9). Anal-
gesic treatment consisting of paracetamol, immediate-release 
tramadol and long-acting tilidine was initiated but quickly 
stopped due to pronounced nausea and vomiting. Treat-
ment with pregabaline (150 mg per day) induced dizziness, 
which was considered as extremely uncomfortable by the 
patient. Finally, a treatment with lidocaine patches (Versa-
tis®; Grünenthal) was initiated. The patient placed 2 patches 
every day in order to cover the entire painful area. After only 
1 week she reported a significant reduction in pain (40% pain 
relief compared to pre-application values). After 4 weeks 
the patient reported a further pain reduction (–75% versus 
pretreatment pain), and an almost completely abolished need 
for systemic analgesics.
Case report 2
A 56-year-old man developed an extremely painful 
  syndrome shortly after a surgical procedure to the right 
foot (microsurgical resection of an interdigital neuroma). 
Despite multiple pharmacological therapies, consisting of 
tramadol, low-dose transdermal fentanyl, amitriptyline, 
gabapentine and venlafaxine, he continued to display severe 
spontaneous burning pain in addition to a pronounced 
mechanical hyperalgesia and allodynia among other symp-
toms. The presence of this NeP syndrome impaired the 
patient’s quality of life in such a way that he had to stop 
working, refused to wear socks and shoes (moving around 
on open sandals) and gave up on almost all of his familial 
and social activities. Daily application of half a lidocaine 
patch onto the painful skin area quickly reduced the evoked 
painful symptoms. A short while later the spontaneous 
pain symptoms also started to decrease. After 8 weeks of 
treatment, overall pain sensations had diminished by 80%. 
The patient reported neither local nor systemic side effects, 
and all other analgesics were stopped. After 12 weeks of 
treatment he resumed work.
Discussion
Treatment of NeP has gone through some significant changes 
in the last decade. Initially, painful neuropathies were treated 
as any other pain syndromes, merely through analgesics. 
Then came more specialized anti-neuropathic treatment 
options, such as Ca2+-channel blockers (gabapentin, pregaba-
lin) and NMDA-receptor antagonists (memantine, ketamine), 
which led to the appearance of (inter)national guidelines 
suggesting a multimodal and balanced treatment of NeP 
(combining analgesics and adjuvants or different classes of 
adjuvant drugs). This change in pharmaceutical approach to 
NeP has been accompanied by a growing tendency towards a 
more mechanism-based treatment. Instead of merely treating 
the painful symptomatology of etiologies, such as diabetes 
and herpes zoster infections, physicians have been slowly 
incorporating underlying pathophysiological mechanisms 
into the choice of treatment options. As a result, application 
of combination and multimodal therapies in the management 
of NeP syndromes has increased.
The introduction of lidocaine-medicated patches should 
mean an additional and significant step into the transgression 
from the classical etiology-based approach to NeP to a much 
more scientifically valid pathophysiology based approach to 
the treatment of painful neuropathies. A specific therapy for 
the injured/excited cutaneous nociceptors is now available 
for the first time. Excited nociceptors are indeed considered 
a crucial part of the pathophysiology of NeP syndromes.7–10 
Lidocaine acts through blockade of abnormally functioning 
(sensitized) Nav 1.7 and Nav 1.8 Na+ channels in dermal 
nociceptors, thereby reducing ectopic discharges.11,12 Lido-
caine has also been shown to regulate T-cell activity and 
inhibit nitric oxide production, thereby reducing inflam-
matory processes within the deep tissue, such as injured 
muscle, joints or constricted nerves.13,14 Certain preclinical 
and clinical findings point towards the existence of addi-
tional biological effects, such as blockage of Aβ-afferents 
conveying allodynia and traveling adjacent to degenerating 
nociceptors within the affected nerve.15 The occurrence of 
a possible central negative feedback signal can be drawn 
from the fact that application of lidocaine patches also has 
been shown to demonstrate an analgesic effect in central 
NeP syndromes.16 The (non)success rate of treatments with 
the lidocaine 5% patches will, however, rely heavily on the 
proper selection of target patients. For this purpose, a clear-
cut and scientifically valid stepwise approach for identifying 
appropriate patients is hereby proposed (see also flow-chart 
diagram, Figure 1).Clinical Pharmacology: Advances and Applications 2010:2 67
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Figure 1 Flow chart for identifying appropriate patients for treatment with lidocaine medicated patches.Clinical Pharmacology: Advances and Applications 2010:2 68
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Who?
Patients should present with a probable diagnosis of NeP, 
considering the recently revised definition and grading 
system.17 Although studies have reported analgesic effects 
of the application of the lidocaine patches in nociceptive 
(non-neuropathic) pain conditions,18–20 the main and most 
appropriate clinical conditions remain superficial localized 
painful neuropathies. Patients should present with a clinical 
history indicative of a NeP syndrome. Neurological examina-
tion and ancillary testing should further confirm the existence 
of a painful neuropathy.
The second, equally important clinical condition is the 
identification of presence of positive cutaneous sensory dis-
turbances. Recent studies have shown the presence of distinct 
symptom profiles in patients suffering from NeP.21 Patients 
should have superficial spontaneous pain (dysesthesia). 
Presence of spontaneous uncomfortable sensory symptoms 
(paresthesias) should be considered as an additional, but 
less crucial, clinical feature. In addition to the occurrence of 
non-evoked pain, presence of hyperalgesia and/or allodynia 
seems crucial. Allodynic complaints should therefore be the 
most prominent clinical symptom of the NeP syndrome in the 
patient. Additional sensory aberrations can be hyperpathia 
and temporal or spatial summation. The diagnostic approach 
to cutaneous NeP syndromes should therefore include the 
proper identification of positive sensory disturbances through 
the use of validated (semi-)quantitative sensory testing 
  methods (such as QST).
In a next step, the physician should clearly identify and 
demarcate the concerned skin area. The physician should 
ensure that its total area is not too out of proportion in 
comparison to the size of the lidocaine patches, so that no 
more than 3 plasters need to be used on a daily basis. In case 
of small skin areas that are painful it is possible to cut the 
patches into smaller pieces to cover the painful skin area. 
  Retrospective analysis of use in daily clinical practice has 
shown a mean value of 0.333 patches per day in our therapies 
of prolonged duration.22 Of course patients should have no 
previous history of allergic reactions to local anesthetics. 
Cardiac disease/renal insufficiency and hepatic disorders do 
not impede the use of lidocaine patches.
Where?
Proper placement of the patches is the next important clinical 
feature. Most clinical studies have described the coverage 
of the entire painful skin area by lidocaine patches. Clinical 
experience, however, tells us that it is not absolutely neces-
sary to cover the entire painful skin area in order to obtain 
optimal analgesic results. Coverage of a large part of the 
painful skin area will in most cases also lead to satisfac-
tory results. It is also proposed that the placement of the 
patches should be altered each day (for example covering 
the proximal versus distal part of the painful dermatome). 
  Presence of allodynia can in a small minority of patients 
lead to exacerbation of pain upon the application of the 
patch. This allodynic flare-up can be prevented by treating 
the patient for a short time with systemic anti-neuropathic 
drugs, such as anti-epileptics.
How?
Patches should be kept on during 12 to 16 consecutive 
hours in a day. Initially, the clinical experience was based 
on a 12 on/of schedule. This treatment schedule was initially 
conceived in order to prevent the occurrence of skin irrita-
tion well before long-term safety data had become available. 
Meanwhile, available safety data have indicated that the 
occurrences of localized skin side effects are minimal with 
application schemes of 12 to 16 consecutive hours. Patches 
can be worn during the day or during the night, depending on 
the exact location of the painful skin area and the adhesive 
ability of the patch on this particular skin site. Physicians 
should note, however, that initially patients will probably 
display some flare up of the pain symptomatology towards 
the end of the off-period. Over time this time-sensitive course 
will, however, (rapidly) decrease. During the first period 
of treatment patients will often report more pronounced 
analgesia during the on-period (patch in place) and increase 
of pain after the patch has been removed. This time pattern 
will change however quickly with continuation of the topical 
treatment.
Follow-up?
If the patch successfully decreases pain, analgesic effects 
should appear rather quickly in a majority of patients. This 
is in great difference with some systemic treatment options 
where positive effects can take up to 6 weeks before reach-
ing a maximum value. The beginning of analgesic effects by 
patch treatment can be expected much sooner, sometimes 
within a couple of days. It is important to mention that appli-
cation of lidocaine 5% patches will not lead to cutaneous 
anesthesia, since there seems to be only minimal effect on 
cutaneous Aβ-fibers (continuous release of low concentra-
tions of lidocaine over 12 to 16 hours). This is in contrast 
with the clear numbness that results from the application of 
lidocaine cream such as Emla® (AstraZeneca) (release of 
high concentration over a short period of time). Over time, Clinical Pharmacology: Advances and Applications 2010:2 69
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the application of lidocaine patches can be decreased to once 
every 48 hours, to 3 times a week, and then further, but years 
of clinical practice has shown that 2 applications a week 
seem to be the absolute minimum.22 In comparison to other 
anti-NeP therapies, the frequency of application should be 
decreased gradually, always observing the absence of flare-up 
before a further reduction is implemented.
Safety aspects?
A growing body of evidence has indicated that side effects 
from the use of lidocaine patches are mostly moderate to 
mild and tend to disappear very quickly after removal of the 
lidocaine medicated patch.23,24 The most common side effect 
is skin irritation (red discoloration) underneath the patch. 
This side effect and its severity can easily be diminished by 
slightly changing the location of the plaster (within the pain-
ful dermatome). Systemic side effects are always absent, even 
during long-term treatment and use of multiple patches on a 
daily basis. This crucial safety aspect can be explained by the 
very low systemic absorption of the lidocaine contained in 
the patches. This unique feature also leads to the absence of 
interactions with concomitant medications that the patient is 
taking (eg, cardiovascular medication, cholesterol-lowering 
drugs, benzodiazepines). The intake of such drugs does not 
need to be halted, or their doses lowered. There is no risk 
for occurrence of systemic side effects. It should, however, 
be stressed that the lidocaine-medicated patches may never 
be applied to open wounds, mucosa or inflamed tissue in 
order to avoid increasing the risk of systemic uptake of the 
lidocaine contained in the patch.
Conclusion
The introduction of the lidocaine-medicated patches 
  constitutes a milestone development in the treatment of 
superficial NeP syndromes. Its rapidly occurring analgesic 
response, low potential for systemic side effects and absence 
of interaction with concomitant medication make this anal-
gesic agent especially suitable for long-term use in patients 
prone to side effects of analgesic agents, or in compromised 
patients with no risk of interactions with concomitant 
medication. The lidocaine-medicated patch constitutes the 
first available therapeutic option with a direct effect on the 
injured or sensitized cutaneous nociceptors. This could make 
a mechanistic approach to NeP a clinical reality.
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